Opioid overdose protection: An inevitable need to address an alarming epidemic

Beatrice Setnik, PhD

doi:10.5055/jom.2017.0414

Authors

Beatrice Setnik, PhD

DOI:

https://doi.org/10.5055/jom.2017.0414

Abstract

-

Author Biography

Beatrice Setnik, PhD

VP Scientific Affairs, Early Phase, INC Research, Raleigh, North Carolina; Adjunct Professor, Department of Pharmacology and Toxicology, University of Toronto, Toronto, Canada

References

Centers for Disease Control and Prevention: Drug overdose deaths in the United States continue to increase in 2015. Available at: https://www.cdc.gov/drugoverdose/epidemic/index.html. Accessed February 15, 2017.

US Department of Health and Human Services: Food and Drug Administration. Center for Drug Evaluation and Research: Abuse-Deterrent Opioids – Evaluation and Labeling. Guidance for Industry. April 2015.

US Department of Health and Human Services: Food and Drug Administration: Fact Sheet–FDA Opioids Action Plan. Available at: http://www.fda.gov/NewsEvents/Newsroom/FactSheets/ucm484714.htm. Accessed February 15, 2017.

Patent PCT/US2015/014690: Abuse-Resistant Drug Formulations with Built-In Overdose Protection. Kashiv Pharma, LLC. Available at: http://patents.justia.com/patent/20160346274. Accessed August 3, 2017.

Cashman JN, Dolin SJ: Respiratory and haemodynamic effects of acute postoperative pain management: evidence from published data. Br J Anaesth. 2004; 93(2): 212-223.

Overdyk FJ, Carter R, Maddox RR, et al.: Continuous oximetry/capnometry monitoring reveals frequent desaturation and bradypnea during patient-controlled analgesia. Anesth Analg. 2007; 105(2): 412-418.

Sivilotti M, Messenger DW, van Vlymen J, et al.: A comparative evaluation of capnometry versus pulse oximetry during procedural sedation and analgesia on room air. CJEM. 2010; 12(5): 397-404.

Setnik B, Cone EJ: Establishing “abuse-deterrence equivalence” for generic abuse-deterrent opioid formulations: A proposed development framework. J Opioid Manag. 2016; 12(2): 96-100.